SCHEDULE 13D/A: Joseph P. Daly Ceases to Hold Reportable Stake in BioCardia, Inc.

Joseph P. Daly has filed an amended Schedule 13D indicating he no longer beneficially owns more than 5% of BioCardia, Inc.'s common stock as of May 13, 2025.

Summary

• This document is an Amendment No. 1 to a Schedule 13D filing by Joseph P. Daly concerning his beneficial ownership of common stock in BioCardia, Inc.
• The filing indicates that as of May 13, 2025, Joseph P. Daly ceased to be the beneficial owner of more than 5% of BioCardia, Inc.'s common stock.
• The reporting person, Joseph P. Daly, is identified as the owner of Essig Research Inc., based in Cincinnati, Ohio.
• No specific purpose of transaction or source of funds for new acquisitions are detailed in this amendment, consistent with a cessation of reportable ownership.
• The filing was signed by Joseph P. Daly on May 21, 2025.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing reporting a change in beneficial ownership status, without providing additional context or forward-looking statements.

Stakeholder Impact

• Shareholders: Will note the change in the beneficial ownership structure of BioCardia, Inc., with Joseph P. Daly no longer holding a reportable stake.

Key Dates

Keywords

BioCardia, Joseph P. Daly, Schedule 13D, beneficial ownership, common stock, SEC filing, ownership change